Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.78)
# 111
Out of 5,056 analysts
25
Total ratings
76.19%
Success rate
29.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $10.34 | +151.45% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $97.06 | +31.88% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $18.83 | +11.52% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $28.52 | +47.27% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $65.83 | +13.93% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $25.14 | +43.20% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $39.43 | +39.49% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $7.67 | +43.42% | 1 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $14.91 | +141.45% | 1 | Aug 19, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.56 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.93 | +34.91% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $90.15 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $31.18 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.54 | - | 1 | Oct 31, 2022 |
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $10.34
Upside: +151.45%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $97.06
Upside: +31.88%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $18.83
Upside: +11.52%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $28.52
Upside: +47.27%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $65.83
Upside: +13.93%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $25.14
Upside: +43.20%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $39.43
Upside: +39.49%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $7.67
Upside: +43.42%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $14.91
Upside: +141.45%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.56
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $5.93
Upside: +34.91%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $90.15
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $31.18
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.54
Upside: -